Method for formulating large diameter synthetic membrane vesicles

Patent metadata

Field	Value
Publication number	US-9757336-B2
Application number	US-201313786945-A
Country	US
Kind code	B2
Filing date	Mar 6, 2013
Priority date	Apr 9, 2010
Publication date	Sep 12, 2017
Grant date	Sep 12, 2017

Abstract

The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.

First claim

What is claimed is:

1. A process for making multivesicular liposomes using an atomizing nozzle apparatus, wherein the apparatus comprises:
a first fluid conduit and a second fluid conduit each having at least one entrance orifice and at least one exit orifice;
a fluid contacting chamber having a top comprising at least one entrance orifice and having a bottom comprising at least one exit orifice and connecting to the at least one exit orifice of the first fluid conduit, wherein the fluid contacting chamber conically narrows in diameter from the top of the fluid contacting chamber to the exit orifice of the fluid contacting chamber; and
a third fluid conduit, wherein the third fluid conduit annularly surrounds a portion of the fluid contacting chamber,
wherein the process for making multivesicular liposomes comprises:
applying a first liquid to the first fluid conduit, wherein the first liquid comprises an organic solvent;
applying a second liquid to the second fluid conduit;
applying a pressurized gas to the third fluid conduit to provide atomized droplets, wherein the pressurized gas exiting the third fluid conduit exit orifice impinges the liquid exiting the fluid contacting chamber exit orifice; and
removing the organic solvent from the atomized droplets, wherein less than 4000 ppm of the organic solvent remains in the atomized droplets, resulting in formation of multivesicular liposomes.

2. The process of claim 1 , wherein the first liquid is an emulsion comprised of:
a discontinuous aqueous phase; and
a continuous organic phase comprising the organic solvent.

3. The process of claim 2 , wherein the organic solvent is methylene chloride or chloroform.

4. The process of claim 2 , wherein the discontinuous aqueous phase further comprises a therapeutic agent.

5. The process of claim 2 , wherein the continuous organic phase further comprises a therapeutic agent.

6. The process of claim 5 , wherein the therapeutic agent is bupivacaine or a salt thereof.

7. The process of claim 1 , wherein the second liquid applied to the second fluid conduit is an aqueous solution.

8. The process of claim 7 , wherein the aqueous solution further comprises either dextrose or lysine, or a mixture thereof.

9. The process of claim 1 , wherein the gas is a sterilized gas.

10. The process of claim 9 , wherein the sterilized gas is nitrogen.

11. The process of claim 1 , wherein the atomized droplets contain organic solvent in the range of from about 400 ppm to about 3500 ppm after solvent removal.

12. The process of claim 4 , wherein the therapeutic agent is bupivacaine or a salt thereof.

13. A process for making multivesicular liposomes using an evaporation apparatus comprising,
wherein the evaporation apparatus comprises:
a solvent removal vessel having a top, a bottom, and a circular wall,
at least one atomizing nozzle,
at least one carrier gas entrance orifice,
a solvent removal gas exit orifice centrally connected to the top, and
a product exit orifice connected to the bottom of the vessel;

wherein the at least one atomizing nozzle comprises:
a first fluid conduit a second fluid conduit each having at least one entrance orifice and at least one exit orifice;
a fluid contacting chamber having a top comprising at least one entrance orifice and having a bottom comprising at least one exit orifice and connecting to the at least one exit orifice of the first fluid conduit, wherein the fluid contacting chamber conically narrows in diameter from the top of the fluid contacting chamber to the exit orifice of the fluid contacting chamber; and
a third fluid conduit, wherein the third fluid conduit annularly surrounds a portion of the fluid contacting chamber,

wherein the process for making multivesicular liposomes comprises:
applying a first liquid to the first fluid conduit, wherein the first liquid comprises an organic solvent;
applying a second liquid to the second fluid conduit;
applying a pressurized gas to the third fluid conduit to provide atomized droplets, wherein the pressurized gas exiting the third fluid conduit exit orifice impinges the liquid exiting the fluid contacting chamber exit orifice; and
removing the organic solvent from the atomized droplets wherein the step of removing the organic solvent from the atomized droplets comprises:
introducing atomized droplets from the at least one atomizing nozzle into the evaporation apparatus,
introducing a pressurized carrier gas tangentially to the circular wall into the solvent removal vessel through one of the at least one carrier gas entrance orifices; and
removing a solvent removal gas wherein the solvent removal gas removes greater than 90% of the organic solvent in the atomized droplets resulting in formation of multivesicular liposomes.

14. The process of claim 13 , wherein the carrier gas is heated and humidified.

15. The process of claim 13 , further comprising spraying a wall rinse solution into the solvent removal vessel using a rinse nozzle, wherein the wall rinse solution prevents build-up of particles in the evaporation apparatus.

Assignees

• Pacira Pharmaceuticals Inc

Inventors

• Schutt Ernest George
• Mcguire Ronald Warren
• Walters Peter Andrew
• Los Kathleen D A

Classifications

• A61P23/02

  Local anaesthetics · CPC title

• A61P23/00

  Anaesthetics · CPC title

• A61K31/445

  Non condensed piperidines, e.g. piperocaine · CPC title

• A61K31/4458 Primary

  only substituted in position 2, e.g. methylphenidate · CPC title

• A61K9/1277

  Preparation processes; Proliposomes · CPC title